Helomics Corporation
Company Information

91 43rd St Ste 220
Pittsburgh, PA, 15201 United States
(412) 432-1500 †

Top 3 Competitors

Unlock more access to Hoover’s!

  • Build customized email lists 24/7, based on your best customer profile.
  • Learn more about the companies you want to sell to. Hoover’s has reports on 85+ million companies and 900 industries. 65,000 data points are updated each day.
  • Get real insight written by real people – exclusive research and reviews by our in-house Editorial staff.
  • We can deliver our data to your desktop, to Excel, direct to your CRM, into your custom app, or via mobile.

Call (866) 473-3932 today to get started with a FREE TRIAL!


Helomics Corporation Company Profile

Helomics knows that chemotherapy isn't "one size fits all." That's why the company developed and markets ChemoFx, a product that examines the response of a specific patient's tumor to various chemotherapies. Physicians can use the test to collect cells from a solid tumor, then Helomics performs tissue cultures and tries various chemotherapeutic and biologic agents to measure the best type, combination, and dose of chemotherapy to help combat the disease in individual patients. The company has been studying ChemoFx use with ovarian and breast tumors, among others. The company markets its products and services through a direct sales force. In late 2016, Helomics was acquired by a group of investors.

The company filed to go public in 2007, but it withdrew its IPO the following year in favor of a proposed merger with blank-check company Oracle Healthcare. However, the merger deal fell through, a casualty of deteriorating economic conditions. Late in the year, Precision Therapeutics raised more than $40 million from private investors, including existing investors Adams Capital Management , Quaker BioVentures, TVM Capital (of Germany), Draper Triangle Ventures , and Birchmere Ventures; it also gained a new investor, Longitude Capital Management.

The cost of ChemoFx at $450 per drug or drug combination tested has economic appeal in addition to its potential scientific usefulness. A single round of chemotherapy can run into the tens of thousands of dollars, but the drugs approved for recurrent ovarian cancer generally only produce responses in 3% to 56% of patients. While still awaiting coverage approval from Medicare, private insurers have been willing to pay for ChemoFx on a case-by-case basis.

† Some telephone numbers on the Hoover’s site may be on a country’s do not call or do not contact list including, but not limited to, the United Kingdom’s CTPS or TPS registers. It is a legal requirement that companies do not make sales or marketing calls to registered numbers. These are central opt out registers whereby corporate subscribers and individuals can register their preference not to receive unsolicited sales and marketing telephone calls. By using the information provided on the Hoover’s sites, as the direct marketer you represent and warrant that you will use such information in compliance with all applicable local, state, national or international laws and regulations, including any local do not call registers or marketing regulations, and agree to defend, indemnify and hold harmless Dun & Bradstreet and each of its affiliates in the event your use violates such laws and regulations.